logo

VMD

Viemed Healthcare·NASDAQ
--
--(--)
--
--(--)
5.96 / 10
Netural

The company exhibits moderate fundamental metrics (6.0/10). Strengths observed in Cash-MV and Net cash flow from operating activities per share (YoY growth rate %), however risks emerge in Net income-Revenue and Asset-MV. Lead to guarded appraisal.

Fundamental(5.96)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value0.46
Score3/3
Weight31.36%
1M Return9.68%
Net cash flow from operating activities per share (YoY growth rate %)
Value42.23
Score3/3
Weight15.38%
1M Return5.16%
Net income-Revenue
Value-1.19
Score0/3
Weight-0.53%
1M Return-0.21%
Basic earnings per share (YoY growth rate %)
Value33.33
Score2/3
Weight7.44%
1M Return2.78%
Total profit (YoY growth rate %)
Value39.48
Score2/3
Weight5.65%
1M Return2.01%
Net cash flow from operating activities (YoY growth rate %)
Value38.89
Score3/3
Weight15.74%
1M Return5.21%
Diluted earnings per share (YoY growth rate %)
Value35.29
Score2/3
Weight6.32%
1M Return2.41%
Asset-MV
Value-0.50
Score1/3
Weight4.77%
1M Return1.95%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value33.76
Score2/3
Weight7.39%
1M Return2.61%
Cash-MV
Value0.52
Score2/3
Weight6.48%
1M Return2.59%
Is VMD undervalued or overvalued?
  • VMD scores 5.96/10 on fundamentals and holds a Fair valuation at present. Backed by its 6.92% ROE, 5.49% net margin, 23.37 P/E ratio, 2.35 P/B ratio, and 29.63% earnings growth, these metrics solidify its Netural investment rating.